O Maas1, F Forrer2, M Maas2, C M Panje3, J Blautzik4, M Brühlmeier5, I Engel-Bicik6, L Giovanella7, A Haldemann8, M E Kamel9, S Kneifel10, C Rottenburger11, N Schaefer12, M A Walter13, S Weidner14, P M Putora3,15. 1. Department of Radiology and Nuclear Medicine, Kantonsspital St. Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland. olechristopher.maas@kssg.ch. 2. Department of Radiology and Nuclear Medicine, Kantonsspital St. Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland. 3. Department of Radiation Oncology, Kantonsspital St. Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland. 4. Department of Radiology and Nuclear Medicine, Hislanden Klinik St. Anna, St. Anna-Strasse 32, 6006, Luzern, Switzerland. 5. Nuclear Medicine and PET-Centre, Kantonsspital Aarau, Tellstrasse 25, 5001, Aarau, Switzerland. 6. Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland. 7. Department of Nuclear Medicine and PET-Centre, Regional Hospital Lugano and Bellinzona, Via Officina 3, 6500, Bellinzona, Switzerland. 8. Department of Radiology and Nuclear Medicine, Stadtspital Triemli, Birmensdorferstrasse 497, 8063, Zurich, Switzerland. 9. Department of Nuclear Medicine, Hôpital du Valais, Av. Grand-Champsec 80, 1951, Sion, Switzerland. 10. Department of Nuclear Medicine, Cantonal Hospital Graubünden Chur, Loëstrasse 170, 7000, Chur, Switzerland. 11. Department of Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland. 12. Department of Nuclear Medicine, University Hospital Lausanne, Rue de Bugnon 46, 1011, Lausanne, Switzerland. 13. Department of Nuclear Medicine, University Hospital Geneva, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland. 14. Department of Nuclear Medicine, Inselspital Bern, Freiburgstrasse 18, 3010, Bern, Switzerland. 15. Department of Radiation Oncology, University of Bern, Bern, Switzerland.
Abstract
BACKGROUND: The role of radioiodine treatment following total thyroidectomy for differentiated thyroid cancer is changing. The last major revision of the American Thyroid Association (ATA) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer in 2015 changed treatment recommendations dramatically in comparison with the European Association of Nuclear Medicine (EANM) 2008 guidelines. We hypothesised that there is marked variability between the different treatment regimens used today. METHODS: We analysed decision-making in all Swiss hospitals offering radioiodine treatment to map current practice within the community and identify consensus and discrepancies. RESULTS AND CONCLUSION: We demonstrated that for low-risk DTC patients after thyroidectomy, some institutions offered only follow-up, while RIT with significant activities is recommended in others. For intermediate- and high-risk patients, radioiodine treatment is generally recommended. Dosing and treatment preparation (recombinant human thyroid stimulation hormone (rhTSH) vs. thyroid hormone withdrawal (THW)) vary significantly among centres.
BACKGROUND: The role of radioiodine treatment following total thyroidectomy for differentiated thyroid cancer is changing. The last major revision of the American Thyroid Association (ATA) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer in 2015 changed treatment recommendations dramatically in comparison with the European Association of Nuclear Medicine (EANM) 2008 guidelines. We hypothesised that there is marked variability between the different treatment regimens used today. METHODS: We analysed decision-making in all Swiss hospitals offering radioiodine treatment to map current practice within the community and identify consensus and discrepancies. RESULTS AND CONCLUSION: We demonstrated that for low-risk DTC patients after thyroidectomy, some institutions offered only follow-up, while RIT with significant activities is recommended in others. For intermediate- and high-risk patients, radioiodine treatment is generally recommended. Dosing and treatment preparation (recombinant human thyroid stimulation hormone (rhTSH) vs. thyroid hormone withdrawal (THW)) vary significantly among centres.
Authors: Thomas Hundsberger; Benedikt Schoser; Daniela Leupold; Kai Michael Rösler; Paul Martin Putora Journal: J Neurol Date: 2019-05-18 Impact factor: 4.849
Authors: Henryk Zulewski; Luca Giovanella; Stefan Bilz; Emanuel Christ; Andreas Haldemann; Hans Steinert; Sabine Weidner; Daniel Oertli; Frédéric Triponez; Thomas Clerici; Anna Minder; Matthias Dettmer; Paul Komminoth Journal: Swiss Med Wkly Date: 2019-01-27 Impact factor: 2.193
Authors: Yuri E Nikiforov; Raja R Seethala; Giovanni Tallini; Zubair W Baloch; Fulvio Basolo; Lester D R Thompson; Justine A Barletta; Bruce M Wenig; Abir Al Ghuzlan; Kennichi Kakudo; Thomas J Giordano; Venancio A Alves; Elham Khanafshar; Sylvia L Asa; Adel K El-Naggar; William E Gooding; Steven P Hodak; Ricardo V Lloyd; Guy Maytal; Ozgur Mete; Marina N Nikiforova; Vania Nosé; Mauro Papotti; David N Poller; Peter M Sadow; Arthur S Tischler; R Michael Tuttle; Kathryn B Wall; Virginia A LiVolsi; Gregory W Randolph; Ronald A Ghossein Journal: JAMA Oncol Date: 2016-08-01 Impact factor: 31.777
Authors: Thomas Steffen; Paul Martin Putora; Martin Hübner; Beat Gloor; Kuno Lehmann; Christoph Kettelhack; Michel Adamina; Ralph Peterli; Jan Schmidt; Frédéric Ris; Markus Glatzer Journal: Clin Colorectal Cancer Date: 2019-06-26 Impact factor: 4.481
Authors: Christian Rothermundt; Alexandra Bailey; Linda Cerbone; Tim Eisen; Bernard Escudier; Silke Gillessen; Viktor Grünwald; James Larkin; David McDermott; Jan Oldenburg; Camillo Porta; Brian Rini; Manuela Schmidinger; Cora Sternberg; Paul M Putora Journal: Oncologist Date: 2015-08-03
Authors: Cédric M Panje; Markus Glatzer; Joscha von Rappard; Christian Rothermundt; Thomas Hundsberger; Valentin Zumstein; Ludwig Plasswilm; Paul Martin Putora Journal: BMC Med Res Methodol Date: 2017-08-16 Impact factor: 4.615